STATEMENT OF STOCKHOLDERS' EQUITY (DEFICIT) - USD ($)	Common Stock	Additional Paid-in Capital	Retained Deficit	Total
Balance at Feb. 28, 2022	$ 131,449	$ 125,708,240	$ (125,838,483)	$ 1,206
Balance (in shares) at Feb. 28, 2022	131,448,444
Increase (Decrease) in Stockholders' Equity
Cash contributed by S.R. Burzynski M.D., Ph.D.		40,517		40,517
FDA clinical trial expenses paid directly by S.R. Burzynski M.D., Ph.D.		151,334		151,334
Net Income (Loss)			(231,737)	(231,737)
Balance at May. 31, 2022	$ 131,449	125,900,091	(126,070,220)	(38,680)
Balance (in shares) at May. 31, 2022	131,448,444
Balance at Feb. 28, 2022	$ 131,449	125,708,240	(125,838,483)	1,206
Balance (in shares) at Feb. 28, 2022	131,448,444
Increase (Decrease) in Stockholders' Equity
Net Income (Loss)				(700,294)
Balance at Nov. 30, 2022	$ 131,449	(126,380,700)	(126,538,777)	(26,628)
Balance (in shares) at Nov. 30, 2022	131,448,444
Balance at May. 31, 2022	$ 131,449	125,900,091	(126,070,220)	(38,680)
Balance (in shares) at May. 31, 2022	131,448,444
Increase (Decrease) in Stockholders' Equity
Cash contributed by S.R. Burzynski M.D., Ph.D.		86,017		86,017
FDA clinical trial expenses paid directly by S.R. Burzynski M.D., Ph.D.		154,943		154,943
Net Income (Loss)			(215,918)	(215,918)
Balance at Aug. 31, 2022	$ 131,449	126,141,051	(126,286,138)	(13,638)
Balance (in shares) at Aug. 31, 2022	131,448,444
Increase (Decrease) in Stockholders' Equity
Cash contributed by S.R. Burzynski M.D., Ph.D.		48,017		48,017
FDA clinical trial expenses paid directly by S.R. Burzynski M.D., Ph.D.		191,632		191,632
Net Income (Loss)			(252,639)	(252,639)
Balance at Nov. 30, 2022	$ 131,449	(126,380,700)	(126,538,777)	(26,628)
Balance (in shares) at Nov. 30, 2022	131,448,444
Balance at Feb. 28, 2023	$ 131,449	126,609,599	(126,754,775)	(13,727)
Balance (in shares) at Feb. 28, 2023	131,448,444
Increase (Decrease) in Stockholders' Equity
Cash contributed by S.R. Burzynski M.D., Ph.D.		64,517		64,517
FDA clinical trial expenses paid directly by S.R. Burzynski M.D., Ph.D.		166,097		166,097
Net Income (Loss)			(287,405)	(287,405)
Balance at May. 31, 2023	$ 131,449	126,840,213	(127,042,180)	(70,518)
Balance (in shares) at May. 31, 2023	131,448,444
Balance at Feb. 28, 2023	$ 131,449	126,609,599	(126,754,775)	(13,727)
Balance (in shares) at Feb. 28, 2023	131,448,444
Increase (Decrease) in Stockholders' Equity
Net Income (Loss)				(972,524)
Balance at Nov. 30, 2023	$ 131,449	127,561,016	(127,727,299)	(34,834)
Balance (in shares) at Nov. 30, 2023	131,448,444
Balance at May. 31, 2023	$ 131,449	126,840,213	(127,042,180)	(70,518)
Balance (in shares) at May. 31, 2023	131,448,444
Increase (Decrease) in Stockholders' Equity
Cash contributed by S.R. Burzynski M.D., Ph.D.		121,017		121,017
FDA clinical trial expenses paid directly by S.R. Burzynski M.D., Ph.D.		197,129		197,129
Net Income (Loss)			(252,104)	(252,104)
Balance at Aug. 31, 2023	$ 131,449	127,158,359	(127,294,284)	(4,476)
Balance (in shares) at Aug. 31, 2023	131,448,444
Increase (Decrease) in Stockholders' Equity
Cash contributed by S.R. Burzynski M.D., Ph.D.		200,605		200,605
FDA clinical trial expenses paid directly by S.R. Burzynski M.D., Ph.D.		202,052		202,052
Net Income (Loss)			(433,015)	(433,015)
Balance at Nov. 30, 2023	$ 131,449	$ 127,561,016	$ (127,727,299)	$ (34,834)
Balance (in shares) at Nov. 30, 2023	131,448,444